Please use this identifier to cite or link to this item:
|Title:||Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.||Austin Authors:||Cliff, Edward R Scheffer;Reynolds, Gemma;Popat, Rakesh;Teh, Benjamin W;Kesselheim, Aaron S;Mohyuddin, Ghulam Rehman||Affiliation:||Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham Women's Hospital, Harvard Medical School, Boston, MA
National Center for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, United Kingdom
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
|Issue Date:||30-Jan-2023||metadata.dc.date:||2023||Publication information:||Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2023||URI:||https://ahro.austin.org.au/austinjspui/handle/1/32065||DOI:||10.1200/JCO.22.02197||ORCID:||0000-0001-5977-907X
|Journal:||Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology||Start page:||JCO2202197||PubMed URL:||36716411||ISSN:||1527-7755||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Mar 30, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.